诊断时大多数患者有1个 (36%[N = 183]) 或2个 (31%[N = 159]) 异常ELN风险定义突变(risk-defining mutations)(ELN 2022指南中可能包含的31个独特细胞遗传学事件和/或突变),见图1B。6%(N= 33) 的患者没有可识别的ELN 风险定义突变或细胞...
根据ELN 2022标准,与中危AML患者相比,低危AML患者的生存期得到了显著改善(HR 0.44;95%CI,0.30-0.65;P<0.001),而不良风险AML患者的生存期显著较差(HR 1.62;95%CI:1.20-2.20;P=0.002);根据ELN 2017标准,与中危AML患者相比,低危AML患者的...
Models excluding results for ASXL1, CEBPA, RUNX1 and TP53, demonstrated that these mutations provide a limited overall contribution to risk stratification across the entire population, given the low frequency of mutations and confounding risk factors. Conclusions: While European LeukemiaNet guidelines ...
在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。本期特整理如下,供大家提前阅览。 研究简介 背景 AML在临床结局和疾病生物学...
European LeukemiaNet (ELN) 2017 updated prognostic system for acute myeloid leukemia (AML), which incorporates both cytogenetic and molecular risks, stratifying patients into 3 distinct genetic risk groups: favorable, intermediate and adverse. While most patients in favorable risk group can be cured wi...
2017ELN:成人AML诊断与治疗推荐(治疗篇) 2010年欧洲白血病网(ELN)对成人AML(急性髓系白血病)的诊断与治疗首次做出推荐,得到认可,在临床实践中广泛应用,事隔7年AML的诊断与治疗有了大量进展,因此ELN对成人AML诊断与治疗推荐做出了更新。2017ELN:成人AML诊断与治疗推荐(诊断篇) ...
amlcg.final: an ExpressionSet that includes the normalized test set gene expression and phenotypic data after filtering to retain probe sets that mapped to transcripts included in the training set mixture cure model amlcg.frame: data.frame that includes the time-to-event outcome (cryr), censoring...
ELN2017 risk group ELN2017-IR vs ELN2017-FR .0003 1.838 1.321 2.557 Transplant, covariate time-dependent Transplant vs no transplant .0185 0.674 0.485 0.936 Discussion In the current analysis, we showed that, when implemented in the prospective, risk-adapted, MRD-driven, AML1310 GIMEMA protocol...
et al. Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. Leukemia 35, 1291–1300 (2021). https://doi.org/10.1038/s41375-020-01031-1 Download citation Received27 April 2020 Revised23 July 2020 Accepted14 August 2020 Published18 ...
AML with MDS-related gene mutations is classified as adverse risk. If adverse-risk cytogenetic abnormalities are present inNPM1-mutated AML, this indicates adverse risk. The presence of in-frame mutations affecting the bZIP region ofCEBPAare classified as favorable risk. ...